Business Wire

New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can ...

In the study, patients with DecisionDx-SCC Class 2B test results, predicted to have the highest risk of metastasis by the test, who were treated with adjuvant radiation therapy (ART) had 50% higher ...
Business Wire

Meta-Analysis Showing DecisionDx-Melanoma Test as Independent, Significant Predictor of Recurrence and Metastatic Risk Presented during Late-Breaking Research Session at the ...

Among these patients, those with a Class 1A (lowest risk) DecisionDx-Melanoma test result had an MSS rate of 98.6%, a risk equivalent to AJCC Stage IA. However, patients in this group who had a Class ...
Nasdaq

New Data Demonstrates Significant and Risk-Appropriate Clinical Impact of DecisionDx-SCC Test Results on Patient Management Decisions

FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today ...
Yahoo Finance

Independent Systematic Review and Meta-Analysis Attests to the Significant Risk Stratification Provided by Castle Biosciences’ DecisionDx®-Melanoma Test, Contributing to ...

"We believe the clinical performance of our DecisionDx-Melanoma test is unmatched by other tests currently on the market, both in its ability to provide precise and clinically meaningful risk ...